Mereo BioPharma Group plc - Sponsored ADR
MREO Healthcare Biotechnology
Mereo BioPharma Group plc - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $500,000.00, down 95.0% from fiscal 2023. In the quarter to June 2026, EPS grew 52.3% and free cash flow grew 21.0%, each against the same quarter a year earlier.
Follow MREO
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | |
|---|---|---|---|---|---|---|---|---|
Cash and Short Term Investments |
40.99 | 69.80 | 57.42 | 68.18 | 129.67 | 30.13 | 20.87 | 36.76 |
Receivables |
— | — | — | — | 3.06 | 2.34 | 1.98 | 0.81 |
Other current assets |
1.50 | 2.79 | 1.18 | 1.57 | — | 3.62 | 13.31 | 7.04 |
Total current assets |
45.02 | 74.76 | 63.76 | 75.20 | 136.58 | 38.17 | 38.86 | 46.04 |
Property, Plant, Equpment (Net) |
0.14 | 0.26 | 0.41 | 0.55 | 3.48 | 2.02 | 14.76 | 0.20 |
Goodwill and Intangible Assets (Total) |
0.52 | 0.64 | 1.09 | — | 33.78 | 40.64 | 56.77 | 43.56 |
Total non-current assets |
0.90 | 1.63 | 2.74 | 2.22 | 37.26 | 42.66 | 71.52 | 43.76 |
Total Assets |
45.92 | 76.39 | 66.50 | 77.41 | 173.84 | 80.82 | 110.39 | 89.80 |
Notes Payable |
— | 5.54 | — | 13.33 | — | — | — | — |
Accounts Payable |
1.33 | 2.44 | 2.35 | 3.49 | 3.44 | 4.28 | 8.11 | 6.10 |
Accrued Expenses |
2.03 | 4.07 | 5.47 | 5.44 | 5.26 | 5.36 | 6.56 | 5.92 |
Current Part of Debt |
— | — | — | — | — | — | 19.33 | 9.13 |
Current Part of Taxes to Pay |
— | — | — | — | 2.09 | — | — | — |
Other current liabilities |
0.74 | 1.10 | 1.02 | 1.56 | 5.60 | 0.54 | 0.85 | 0.44 |
Total current liabilities |
4.30 | 13.85 | 9.49 | 24.38 | 17.25 | 11.00 | 38.15 | 21.59 |
Long Term Debt (Total) |
— | — | 4.39 | — | 19.78 | 20.73 | 6.86 | 19.55 |
Non-current Liabilities (Other) |
0.70 | 1.39 | 1.18 | 0.16 | 13.39 | 66.84 | 2.07 | 4.91 |
Total non-current liabilities |
0.70 | 1.57 | 6.48 | 1.64 | 35.58 | 89.05 | 20.83 | 24.46 |
Total liabilities |
5.00 | 15.42 | 15.96 | 26.01 | 52.82 | 100.05 | 58.98 | 46.06 |
Additional Paid In Capital |
549.62 | 539.64 | 486.11 | 476.52 | 518.82 | 372.56 | 230.90 | 182.98 |
Common Stock (Net) |
3.14 | 3.06 | 2.78 | 2.48 | 2.41 | 1.31 | 0.38 | 0.29 |
Retained Earnings |
(501.02) | (462.88) | (419.63) | (404.57) | (408.36) | (397.65) | (186.51) | (148.46) |
Treasury Stock |
— | — | 1.23 | 1.34 | — | — | — | — |
Shareholders Equity (Other) |
— | — | — | — | 8.14 | 4.55 | 6.63 | 8.93 |
Common Equity (Total) |
40.92 | 60.97 | 50.54 | 51.40 | 121.01 | (19.22) | 51.40 | 43.74 |
Shareholders Equity (Total) |
40.92 | 60.97 | 50.54 | 51.40 | 121.01 | (19.22) | 51.40 | 43.74 |
Shareholders Equity and Liabilities (Total) |
45.92 | 76.39 | 66.50 | 77.41 | 173.84 | 80.82 | 110.39 | 89.80 |
Shares (Common) |
159.13 | 155.15 | 140.06 | 124.79 | 116.98 | 67.79 | 19.59 | 14.25 |
Shareholders Equity (Tangible) |
40.40 | 60.33 | 49.45 | 51.40 | 87.23 | (59.86) | (5.36) | 0.18 |
Net Debt |
(40.99) | (69.80) | (53.03) | (68.18) | (109.89) | (9.41) | 5.32 | (8.09) |
Total Debt |
— | — | 4.39 | — | 19.78 | 20.73 | 26.19 | 28.68 |